PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26022F0215Berotralstat HCL 150mg CAP ORAL BULK — Biocryst Pharmaceuticals, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended May 31, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Biocryst Pharmaceuticals, Inc

Recipient

May 31, 2023

PoP end

$113K

Obligated

$369K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Biocryst Pharmaceuticals, Inc — $90

Contract facts

Federal

Contract number36C26022F0215

Also listed as36C260-22-F-0215

Also listed as36F79721D0166-36C26022F0215

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentBiocryst Pharmaceuticals, Inc

CAGE4GBX7

UEIMGXADJ6SCLJ5

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79721D0166

Place of performanceDURHAM NC

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startJun 1, 2022

PoP end (current)May 31, 2023

Obligated$113K

Current value$369K

Potential value$369K

BEROTRALSTAT HCL 150MG CAP,ORAL BULK, 72769-0101-01 is a federal award for 260-Network Contract Office 20 (36C260) held by Biocryst Pharmaceuticals, Inc. Estimated value $369K ($113K obligated). Current period of performance ends May 31, 2023. Last award drew 1 bidder. Place of performance: DURHAM NC.

BEROTRALSTAT HCL 150MG CAP,ORAL BULK, 72769-0101-01

Recompete timing

Public

● Past PoP end (1178 days ago)

Current PoP ended May 31, 2023 (1178 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26022F0215?

36C26022F0215 (Berotralstat HCL 150mg CAP ORAL BULK) is a 260-Network Contract Office 20 (36C260) award with a potential value of $369K, currently held by Biocryst Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-22-F-0215?

36C260-22-F-0215 is the dashed form of PIID 36C26022F0215 (Berotralstat HCL 150mg CAP ORAL BULK), held by Biocryst Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26022F0215?

260-Network Contract Office 20 (36C260) awarded 36C26022F0215 to Biocryst Pharmaceuticals, Inc (potential $369K).

Who is the incumbent on 36C26022F0215?

Biocryst Pharmaceuticals, Inc is the incumbent. The current period of performance ends May 31, 2023.

When does Biocryst Pharmaceuticals, Inc’s 36C26022F0215 come up for recompete?

SCOUT tracks a period-of-performance end of May 31, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Sep 14, 2023 · refreshed monthly